Identifying Flare Prone Spondyloarthritis: Insights From a Prospective Cohort.

Cureus · 2026 · PMC13200224 · PMID 42199594

Europe PMC DOI

hedged sentence

0.2490

closest p · 5.0× alpha

0.2490

boldest claim

The sentences

did not reach statistical significancep = 0.249not close (p > 0.1)

The median time to flare was longer in patients receiving biologic or targeted synthetic DMARDs (88 days vs 26 days), although this difference did not reach statistical significance (p = 0.249).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.